Sarclisa (isatuximab)

pCPA File Number: 21444
Negotiation Status:
Under consideration for negotiation
Indication(s):
Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Sponsor/Manufacturer:
Sanofi Genzyme
CADTH Project Number:
PC0220-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable